Context Therapeutics Inc. (CNTX) – What Are Analysts Thinking About This Stock?

Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $6.40.

Several brokerages have recently commented on CNTX. Lifesci Capital downgraded shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Wall Street Zen cut shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Citigroup reissued an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 15th. Finally, Zacks Research raised shares of Context Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday.

Check Out Our Latest Stock Report on Context Therapeutics

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CNTX. Sanctuary Advisors LLC bought a new position in Context Therapeutics during the 1st quarter valued at approximately $51,000. Two Sigma Securities LLC grew its holdings in shares of Context Therapeutics by 388.7% in the second quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock worth $34,000 after acquiring an additional 48,871 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Context Therapeutics during the 2nd quarter valued at about $29,000. Bank of America Corp DE bought a new position in Context Therapeutics in the second quarter worth approximately $30,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Context Therapeutics in the 1st quarter worth $211,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Performance

CNTX opened at $0.20 on Friday. The stock’s 50 day simple moving average is $0.29 and its 200 day simple moving average is $1.38. Context Therapeutics has a 1 year low of $0.18 and a 1 year high of $3.62.

Context Therapeutics (NASDAQ:CNTX – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Analysts expect that Context Therapeutics will post -0.47 EPS for the current fiscal year.

Context Therapeutics Company Profile

(Get Free Report)

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens. Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.

Featured Articles

Analyst Recommendations for Context Therapeutics (NASDAQ:CNTX)

Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.